Related Experiment Videos
A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters
Cassiana R G Giribela1, Nilson R Melo, Rita C G Silva
1Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil. cgiribela@uol.com.br
Background:
Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, possibly associated with changes in blood pressure and endothelial function.
Study Design:
The objective was to evaluate the impact of COC containing 20 mcg of ethinylestradiol (EE) and 3 mg of drospirenone (DRSP) on the arterial endothelial function, systolic and diastolic blood pressure (SBP and DBP , respectively), heart rate (HR), cardiac output (CO) and total peripheral resistance (TPR) of healthy young women. Of the 71 women in the study, 43 were evaluated before the introduction of COC and after 6 months of its use (case group) and 28, COC nonusers, were assessed for the same parameters at the same time interval (control group).
Results:
No significant changes in endothelium-dependent and endothelium-independent functions or in measures of SBP, DBP, HR, CO and TPR caused by COC use were observed in the case group (p>.05 for all variables) or in the control group.
Conclusion:
These data suggest COC with 20 mcg EE and 3 mg DRSP does not alter arterial endothelial function or hemodynamic parameters in healthy young women.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Birth Control Methods
Antihypertensive Drugs: Vasodilators
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Clinical Trials: Overview